BioCentury | Feb 15, 2010
Company News

Nucryst deal

...in cash per Nucryst share owned. The deal follows the acquisition of substantially all of Nucryst's...
BioCentury | Jan 4, 2010
Company News

Nucryst, Smith & Nephew deal

...its previously announced acquisition of substantially all of Nucryst's assets (see BioCentury, Nov. 16, 2009). Nucryst Pharmaceuticals Corp....
BioCentury | Nov 16, 2009
Company News

Nucryst, Smith & Nephew deal

...Smith & Nephew will acquire substantially all of Nucryst's assets for $21 million in cash, plus...
...assets for $21 million in cash, plus the value of working capital. The sale includes Nucryst's...
...one preferred share redeemable for $1.77 in cash per Nucryst share owned. At June 30, Nucryst...
BioCentury | Sep 28, 2009
Financial News

Nucryst financial update

...bid price requirement for continued listing. The company has until March 15 to regain compliance. Nucryst Pharmaceuticals Corp....
BioCentury | Sep 14, 2009
Company News

Smith & Nephew sales and marketing update

...dressings in the EU for wound care. The products use Silcryst nanocrystalline silver coatings from Nucryst Pharmaceuticals Corp....
BioCentury | May 18, 2009
Company News

Nucryst infectious news

...also eliminated spending on undisclosed development programs until it secures commercialization partners for the programs. Nucryst's...
...is a nanocrystalline silver powder in development to treat Clostridium difficile infection. At March 31, Nucryst...
...million. At Dec. 31, 2008, the company had a 12-month operating loss of $6.1 million. Nucryst Pharmaceuticals Corp....
BioCentury | Feb 2, 2009
Company News

Nucryst management update

Nucryst Pharmaceuticals Corp. (NASDAQ:NCST, TSX:NCS), Princeton, N.J. Business: Dermatology, Autoimmune, Gastrointestinal Resigned: Thomas Gardner as president, CEO and chairman; David Holtz will serve as interim president and CEO while remaining CFO; Neil Carragher, a director,...
BioCentury | May 12, 2008
Company News

Nucryst management update

Nucryst Pharmaceuticals Corp. (NASDAQ:NCST, TSX:NCS), Wakefield, Mass. Business: Dermatology Hired: David Holtz as VP and CFO, formerly SVP of finance at Integra LifeSciences Holdings Corp. WIR Staff Dermatology...
BioCentury | May 5, 2008
Company News

Interleukin Genetics management update

...Pharmacogenetics Hired: Eliot Lurier as CFO, formerly VP of finance and administration and CFO of Nucryst Pharmaceuticals Corp. WIR...
BioCentury | May 5, 2008
Clinical News

NPI 32101: Development discontinued

...32101 to treat IBD, but will continue to develop it to treat Clostridium difficile infection. Nucryst Pharmaceuticals Corp....
Items per page:
1 - 10 of 26
BioCentury | Feb 15, 2010
Company News

Nucryst deal

...in cash per Nucryst share owned. The deal follows the acquisition of substantially all of Nucryst's...
BioCentury | Jan 4, 2010
Company News

Nucryst, Smith & Nephew deal

...its previously announced acquisition of substantially all of Nucryst's assets (see BioCentury, Nov. 16, 2009). Nucryst Pharmaceuticals Corp....
BioCentury | Nov 16, 2009
Company News

Nucryst, Smith & Nephew deal

...Smith & Nephew will acquire substantially all of Nucryst's assets for $21 million in cash, plus...
...assets for $21 million in cash, plus the value of working capital. The sale includes Nucryst's...
...one preferred share redeemable for $1.77 in cash per Nucryst share owned. At June 30, Nucryst...
BioCentury | Sep 28, 2009
Financial News

Nucryst financial update

...bid price requirement for continued listing. The company has until March 15 to regain compliance. Nucryst Pharmaceuticals Corp....
BioCentury | Sep 14, 2009
Company News

Smith & Nephew sales and marketing update

...dressings in the EU for wound care. The products use Silcryst nanocrystalline silver coatings from Nucryst Pharmaceuticals Corp....
BioCentury | May 18, 2009
Company News

Nucryst infectious news

...also eliminated spending on undisclosed development programs until it secures commercialization partners for the programs. Nucryst's...
...is a nanocrystalline silver powder in development to treat Clostridium difficile infection. At March 31, Nucryst...
...million. At Dec. 31, 2008, the company had a 12-month operating loss of $6.1 million. Nucryst Pharmaceuticals Corp....
BioCentury | Feb 2, 2009
Company News

Nucryst management update

Nucryst Pharmaceuticals Corp. (NASDAQ:NCST, TSX:NCS), Princeton, N.J. Business: Dermatology, Autoimmune, Gastrointestinal Resigned: Thomas Gardner as president, CEO and chairman; David Holtz will serve as interim president and CEO while remaining CFO; Neil Carragher, a director,...
BioCentury | May 12, 2008
Company News

Nucryst management update

Nucryst Pharmaceuticals Corp. (NASDAQ:NCST, TSX:NCS), Wakefield, Mass. Business: Dermatology Hired: David Holtz as VP and CFO, formerly SVP of finance at Integra LifeSciences Holdings Corp. WIR Staff Dermatology...
BioCentury | May 5, 2008
Company News

Interleukin Genetics management update

...Pharmacogenetics Hired: Eliot Lurier as CFO, formerly VP of finance and administration and CFO of Nucryst Pharmaceuticals Corp. WIR...
BioCentury | May 5, 2008
Clinical News

NPI 32101: Development discontinued

...32101 to treat IBD, but will continue to develop it to treat Clostridium difficile infection. Nucryst Pharmaceuticals Corp....
Items per page:
1 - 10 of 26